University Study Validates Patented Maitake Extract’s Superior Immunostimulating Properties

December 14, 2005 - In a new study recently published in the peer reviewed Journal of the American Nutraceutical Association (JANA) (Vol. 8, No.3,2005), researcher and author Dr. Vaclav Vetvicka of the University of Louisville compared the immunostimulating properties of two different maitake mushroom glucan extracts, one being MaitakeGold 404®, against Lentinan, a pharmaceutical which contains a standard, well-researched mushroom derived glucan. Lentinan has been used clinically for immunotherapy in Japan for over 25 years and is considered the benchmark in mushroom derived glucans.

The study showed that MaitakeGold 404®, when compared with the other maitake extract and Lentinan had the highest level of stimulation in the greatest number of immune categories tested. In the study, MaitakeGold 404® via oral administration caused direct stimulation of cells involved in immune reactions as well as the release of numerous cytokines necessary for immune response and defense. MaitakeGold 404® was shown to be effective even in relatively small doses compared to the other tested agents.

The patented extract MaitakeGold 404®, marketed by the Tradeworks Group, Inc. is currently being used exclusively in a multi-phase U.S. Government funded human clinical trial at Memorial Sloan Kettering Cancer Center. The extract has received an Investigational New Drug number (IND) in conjunction with the trial. The extract is also being evaluated in a 5 year study at Memorial Sloan Kettering along with other botanical agents assessing their immunomodulation activity, this study is funded by a grant from the National Institutes of Health (NIH).

This current research clearly demonstrates that Maitake extracts used as dietary supplements, in particular MaitakeGold 404®, provide a generally high level of immune stimulation, are relatively more biologically and immunologically active than the drug Lentinan and substantially do not lose their biological activity when administered orally.

“This is great news for the Tradeworks Group and our marketing partners utilizing MaitakeGold 404® in their supplement brands” says Tradeworks Group President Peter McNeary. McNeary further stated, “the Tradeworks Group has experienced a sales increase of more than 110 percent in 2005, which we attribute in part to the disclosure that the extract is being used in a clinical trial at one of the world’s leading Research Centers.”

MaitakeGold 404® is available as a bulk branded ingredient and is marketed in leading, nationally distributed supplement brands.

For additional information, visit,
Memorial Sloan Kettering Cancer Center
The Journal of the American Nutraceutical Association

Tradeworks Group, Inc. of Vermont is a leading developer and marketer of proprietary bulk branded ingredients to the nutraceutical industry. MaitakeGold 404® is a registered trademark of the Tradeworks Group, Inc.

For more information contact:

Lorna Kazokas
Tradeworks Group, Inc.
167 Main Street
Brattleboro, VT 05301
Tel. 802-257-2440
Fax 802-257-2445

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.